Achieve Life Sciences carries the trial record of OncoGenex, whose antisense drug custirsen failed phase 3 trials in prostate and lung cancer before the company turned to a smoking-cessation medicine.
OncoGenex Pharmaceuticals, founded in 2000 in Bothell, Washington, developed custirsen (OGX-011), an antisense inhibitor of clusterin, and led the phase 3 SYNERGY and AFFINITY trials in metastatic castration-resistant prostate cancer and a phase 3 trial in non-small cell lung cancer, none of which improved survival. In 2017 it merged with Achieve Life Sciences, which now develops cytisinicline for smoking cessation, a cancer prevention aim. The custirsen trials sit on ClinicalTrials.gov under the Achieve name.
A drug designed to switch off a protein that helps cancer cells survive chemotherapy. Two large trials found it added nothing.
Shares Oligonucleotide therapeutics, Prostate cancer, Non-small-cell lung cancer.
Shares AFFINITY, SYNERGY, Oligonucleotide therapeutics, Prostate cancer.
Shares AFFINITY, Prostate cancer.
Shares SYNERGY, Prostate cancer.
Shares AFFINITY, Prostate cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/